1. Home
  2. MITQ vs INDP Comparison

MITQ vs INDP Comparison

Compare MITQ & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Moving iMage Technologies Inc.

MITQ

Moving iMage Technologies Inc.

HOLD

Current Price

$0.62

Market Cap

5.9M

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$1.17

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MITQ
INDP
Founded
N/A
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9M
5.2M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
MITQ
INDP
Price
$0.62
$1.17
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
202.0K
38.0K
Earning Date
05-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$20,139,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$58.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.42
$0.27
52 Week High
$1.66
$13.24

Technical Indicators

Market Signals
Indicator
MITQ
INDP
Relative Strength Index (RSI) 52.36 27.50
Support Level $0.57 N/A
Resistance Level $0.64 $2.08
Average True Range (ATR) 0.04 0.23
MACD -0.00 -0.11
Stochastic Oscillator 67.34 17.79

Price Performance

Historical Comparison
MITQ
INDP

About MITQ Moving iMage Technologies Inc.

Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: